National Academies Press: OpenBook

Diagnosing and Treating Adult Cancers and Associated Impairments (2021)

Chapter: Appendix A: Biographical Sketches of Committee Members and Consultant

« Previous: 10 Survivorship Outcomes and Care Delivery
Suggested Citation:"Appendix A: Biographical Sketches of Committee Members and Consultant." National Academies of Sciences, Engineering, and Medicine. 2021. Diagnosing and Treating Adult Cancers and Associated Impairments. Washington, DC: The National Academies Press. doi: 10.17226/25956.
×
Page 345
Suggested Citation:"Appendix A: Biographical Sketches of Committee Members and Consultant." National Academies of Sciences, Engineering, and Medicine. 2021. Diagnosing and Treating Adult Cancers and Associated Impairments. Washington, DC: The National Academies Press. doi: 10.17226/25956.
×
Page 346
Suggested Citation:"Appendix A: Biographical Sketches of Committee Members and Consultant." National Academies of Sciences, Engineering, and Medicine. 2021. Diagnosing and Treating Adult Cancers and Associated Impairments. Washington, DC: The National Academies Press. doi: 10.17226/25956.
×
Page 347
Suggested Citation:"Appendix A: Biographical Sketches of Committee Members and Consultant." National Academies of Sciences, Engineering, and Medicine. 2021. Diagnosing and Treating Adult Cancers and Associated Impairments. Washington, DC: The National Academies Press. doi: 10.17226/25956.
×
Page 348
Suggested Citation:"Appendix A: Biographical Sketches of Committee Members and Consultant." National Academies of Sciences, Engineering, and Medicine. 2021. Diagnosing and Treating Adult Cancers and Associated Impairments. Washington, DC: The National Academies Press. doi: 10.17226/25956.
×
Page 349
Suggested Citation:"Appendix A: Biographical Sketches of Committee Members and Consultant." National Academies of Sciences, Engineering, and Medicine. 2021. Diagnosing and Treating Adult Cancers and Associated Impairments. Washington, DC: The National Academies Press. doi: 10.17226/25956.
×
Page 350
Suggested Citation:"Appendix A: Biographical Sketches of Committee Members and Consultant." National Academies of Sciences, Engineering, and Medicine. 2021. Diagnosing and Treating Adult Cancers and Associated Impairments. Washington, DC: The National Academies Press. doi: 10.17226/25956.
×
Page 351
Suggested Citation:"Appendix A: Biographical Sketches of Committee Members and Consultant." National Academies of Sciences, Engineering, and Medicine. 2021. Diagnosing and Treating Adult Cancers and Associated Impairments. Washington, DC: The National Academies Press. doi: 10.17226/25956.
×
Page 352
Suggested Citation:"Appendix A: Biographical Sketches of Committee Members and Consultant." National Academies of Sciences, Engineering, and Medicine. 2021. Diagnosing and Treating Adult Cancers and Associated Impairments. Washington, DC: The National Academies Press. doi: 10.17226/25956.
×
Page 353
Suggested Citation:"Appendix A: Biographical Sketches of Committee Members and Consultant." National Academies of Sciences, Engineering, and Medicine. 2021. Diagnosing and Treating Adult Cancers and Associated Impairments. Washington, DC: The National Academies Press. doi: 10.17226/25956.
×
Page 354

Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Appendix A Biographical Sketches of Committee Members and Consultant COMMITTEE MEMBERS Dan G. Blazer II, M.D., M.P.H., Ph.D. (Chair), is the J.P. Gibbons Professor Emeritus of Psychiatry and Behavioral Sciences and a professor of commu- nity and family medicine at the Duke University School of Medicine, and he also serves as an adjunct professor in the Department of Epidemiology at the University of North Carolina Gillings School of Global Public Health. He is the author or the co-author of more than 180 books chapters, more than 220 published abstracts, and nearly 500 peer-reviewed articles. He is also the editor or the author of 40 books. He has served as the principal investigator (PI) of the Duke University Established Populations for Epide- miologic Studies of the Elderly, the Piedmont Health Survey of the Elderly, and the MacArthur Field Studies of Successful Aging. He also was the origi- nal PI of the Duke Clinical Research Center for the Study of Depression in Late Life. Dr. Blazer is an elected member of the National Academy of Medicine from which he received the Walsh McDermott Award for Distin- guished Lifetime Service to the Academy. For the National Academies of Sciences, Engineering, and Medicine, Dr. Blazer has served as the chair of the Board on the Health of Select Populations, as a member of the Board on Population Health and Public Health Practice, and has chaired multiple consensus committees. Dr. Blazer is the recipient of the first Annual Geriat- ric Psychiatry Research Award and the Distinguished Service Award from the American College of Psychiatrists, the Weinberg Award for geriatric psychiatry and the Oscar Pfister Award for the integration of religion and 345 PREPUBLICATION COPY—Uncorrected Proofs

346 DIAGNOSING AND TREATING ADULT CANCERS psychiatry from the American Psychiatric Association, the Klemeier Award from the Gerontological Society of America, the Rema Lapouse Award from the American Public Health Association, the Distinguished Faculty Award from the Duke University School of Medicine, the Distinguished Alumni Award from the University of North Carolina Gillings School of Global Public Health and the University of Tennessee School of Medicine, and the Senior Investigator Award from the American Association of Ge- riatric Psychiatry. He received his M.D. from the University of Tennessee, Memphis, and his M.P.H. and Ph.D. from the University of North Carolina at Chapel Hill. Alex A. Adjei, M.D., Ph.D., is a professor of oncology and pharmacology in the Mayo College of Medicine. He is also a consultant in medical oncology at the Mayo Clinic, the director of the Early Cancer Therapeutics Program, and the leader of the Lung Cancer Program across all three Mayo Clinic sites, and he is the principal investigator (PI) for the Mayo phase I and phase II National Cancer Institute (NCI) grants. Dr. Adjei has served on a number of NCI committees and is currently the co-chair of the Thoracic Malignancies Steering Committee and the editor-in-chief of the Journal of Thoracic Oncology. His research is focused on experimental therapeutics and clinical drug development, and he received the first American Society of Clinical Oncology (ASCO) Drug Development Research Professorship 2012–2017 in recognition of his mentorship and his work in cancer drug development. He has authored 260 publications dealing primarily with preclinical pharmacology and phase I trials as well as novel therapeutics/ phase II trials of lung cancer. He received his Ph.D. from the University of Alberta and M.D. from the University of Ghana Medical School. Dr. Adjei is the PI for 10 clinical trials. Funding from the pharmaceutical companies for the trials goes to the Mayo Clinical Research Center. Wallace Akerley, M.D., is the director of the Huntsman Cancer Institute Lung Cancer Disease Center and a professor of internal medicine at The University of Utah. He is board certified in oncology and hematology. He has been active in clinical research for more than 20 years. He continues leadership roles in the Huntsman Intermountain Cancer Care Program, a community–academic collaboration as the chair of the Protocol Review and Monitoring Committee and a member of the Clinical Research Executive Committee. Dr. Akerley is the principal investigator (PI) for two active insti- tutional trials and the institutional PI for 16 national clinical trials. Funding from Bristol-Myers Squibb, NovoCure, Pfizer, Novartis, lncyte, CytomX, Loxo, and Biodesix for drugs and data management and analysis goes to the Huntsman Cancer Institute. Dr. Akerley is a member of two Eli Lilly and Company–sponsored trials, the data safety and monitoring board for PREPUBLICATION COPY—Uncorrected Proofs

APPENDIX A 347 selpercatinib in thyroid cancer (chair), and for non-small-cell lung cancer (member). Jose G. Bazan, Jr., M.D., is an associate professor of radiation oncology at The Ohio State University with clinical expertise in treating breast cancer and non-small-cell carcinomas of the lung. He has published in a variety of medical journals such as the International Journal of Radiation Oncology, Biology, Physics, the Journal of Thoracic Oncology, the Journal of Nuclear Medicine, Practical Radiation Oncology, and Clinical Lung Cancer. Dr. Bazan has been the principal investigator (PI) for several clinical trials and is currently the PI for the Multi-Institution Phase II Trial of Intraoperative Electron Beam Radiotherapy Boost at the Time of Breast-Conserving Sur- gery with Oncoplastic Reconstruction in Women with Early-Stage Breast Cancer. Funding from the medical device manufacturer for this trial goes to The Ohio State University. He received his M.D. from Stanford University. Gabriel A. Brooks, M.D., M.P.H., is an assistant professor of medicine and an assistant professor of The Dartmouth Institute for Health Policy and Clinical Practice at the Geisel School of Medicine at Dartmouth College. He is a health services researcher with a focus on improving the quality and value of cancer treatments. In his clinical practice he treats patients with gastrointestinal cancers, including colorectal, gastric, pancreas, and hepa- tobiliary cancers. He received his M.D. from the University of Pennsylvania Perelman School of Medicine and his M.P.H from the Harvard T.H. Chan School of Public Health. Dr. Brooks is a site principal investigator (PI) for cancer clinical trials with a mix of public and private funding, including three multi-institution clinical trials with pharmaceutical industry funding. Pharmaceutical company payments for these trials go to the Dartmouth- Hitchcock Medical Center; Dr. Brooks does not receive any payments for his role as the site PI. Deborah W. Bruner, Ph.D., R.N., is the senior vice president for research, a professor and the Robert W. Woodruff Chair in nursing, and a professor of radiation oncology at Emory University. She is an internationally renowned researcher and clinical trialist with a focus on patient-reported outcomes, symptom management, and the comparative effectiveness of radiotherapy modalities. Recognition of her work led to her appointment by President Obama to one of only two National Institutes of Health presidential-ap- pointed committees, the National Cancer Institute’s National Cancer Advi- sory Board, on which she still serves. Dr. Bruner is the first and only nurse to ever lead a national clinical trials cooperative group, first as the principal investigator (PI) of the Radiation Therapy Oncology Group Community Clinical Oncology Program and currently as the multi-PI of the NRG PREPUBLICATION COPY—Uncorrected Proofs

348 DIAGNOSING AND TREATING ADULT CANCERS Oncology group National Community Oncology Research Program. She is a member of the National Academy of Medicine and has won numerous awards for research and mentorship. Dr. Bruner received her Ph.D. in nurs- ing, with a focus on outcomes research, at the University of Pennsylvania. Grace B. Campbell, Ph.D., M.S.W., R.N., is an assistant professor in the Department of Acute and Tertiary Care at the University of Pittsburgh School of Nursing. Her research involves assessing the impact of chronic disorders on physical function and developing behavioral interventions to improve physical function as well as using novel technologies to measure physical function in naturalistic settings. She is currently conducting a lon- gitudinal study exploring the development and progression of chemother- apy-induced peripheral neuropathy and its related functional impairments in women with ovarian cancer, which is funded by the Oncology Nursing Society, and a scale-up implementation study of use of an m-Health be- havioral intervention to improve function and social participation among women with gynecologic cancer and their family caregivers funded by the National Institute on Disability, Independent Living, and Rehabilitation Research. She is a member of the Association of Rehabilitation Nurses, American Congress of Rehabilitation Medicine, Oncology Nursing Society, and Eastern Nursing Research Society; she serves as a subject-matter expert for cancer rehabilitation on the National Institutes of Health’s Clinical Cen- ter’s Cancer Rehabilitation Expert Consortium; and she is a member of the editorial board of the Rehabilitation Nursing Journal. She also is a mem- ber of the National Academies of Sciences, Engineering, and Medicine’s Roundtable on Quality Care for People with Serious Illness. She received her M.S.W. and Ph.D. from the University of Pittsburgh. Susan M. Domchek, M.D., is the Basser Professor in Oncology at the University of Pennsylvania Perelman School of Medicine. She serves as the executive director of the Basser Center for BRCA at the Abramson Cancer Center and the director of the Mariann and Robert MacDonald Cancer Risk Evaluation Program. Her work focuses on the genetic evaluation and medical management of individuals with inherited risk factors for cancer. Dr. Domchek is particularly interested in developing new cancer therapies, such as PARP inhibitors, for breast cancer linked to genetic risk factors. She has been the principal investigator on multiple trials investigating new therapeutic agents for cancer. An elected member of the American Society of Clinical Investigation and the Association of American Physicians, Dr. Domchek is also a member of the American Society of Clinical Oncol- ogy, for which she had served on a number of committees, and is a newly elected member of the National Academy of Medicine (2018). A significant contributor to the oncology literature, she has authored or co-authored PREPUBLICATION COPY—Uncorrected Proofs

APPENDIX A 349 more than 300 articles appearing in scholarly journals, including the New England Journal of Medicine, JAMA, and the Journal of Clinical Oncology. Dr. Domchek also serves on a number of editorial review boards, including Cancer Discovery, as well as on the scientific advisory board for the Breast Cancer Research Foundation. She received her M.D. from the Harvard Medical School. In the past 2 years, Dr. Domchek has received honoraria from Bristol-Meyers Squibb, Clovis, and AstraZeneca. The University of Pennsylvania has received research funds from AstraZeneca and Clovis for research studies run by Dr. Domchek. Patricia A. Ganz, M.D., is the associate director for population science research at the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles (UCLA). She is a pioneer in the assessment of the quality of life in cancer patients and survivors and is active in clinical trials research with NRG Oncology, a federally funded clinical trials group. She has focused much of her clinical and research efforts in the areas of breast cancer and its prevention and was a member of the National Cancer Insti- tute Progress Review Group on Breast Cancer. She established the UCLA Family Cancer Registry and Genetic Evaluation Program, which serves patients and survivors as well as those at high risk for familial/hereditary cancers. Her other major areas of research include cancer survivorship and the late effects of cancer treatment, cancer in the elderly, and the quality of care for cancer patients. Dr. Ganz served on the Institute of Medicine (IOM) committee responsible for the 2005 report From Cancer Patient to Survivor: Lost in Transition and on the 2008 IOM committee for the report Cancer Care for the Whole Patient: Meeting Psychosocial Health Needs, and she chaired the consensus study report Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis in 2013. She served on the IOM National Cancer Policy Forum from 2009 to 2016. In 2017 she became the editor-in-chief of the Journal of the National Cancer Institute and she is on the editorial board of the Journal of Cancer Survivorship. She was a founding member of the National Coalition for Cancer Survivorship in 1986 and has directed the UCLA–Livestrong Survivorship Center of Ex- cellence at the Jonsson Comprehensive Cancer Center since 2006. Dr. Ganz was elected to the National Academy of Medicine in 2007. She received her M.D. from UCLA. Dr. Ganz is the co-investigator on two NRG Oncology clinical trials (as supervisor of the patient-reported outcomes component) that have partial funding from Merck and Genentech to provide support for drugs and analyses being conducted by NRG Oncology. Rosa Hwang, M.D., is a professor at the University of Texas MD Ander- son Cancer Center (MDACC) with joint appointments in the departments of breast surgical oncology and surgical oncology. She is currently also PREPUBLICATION COPY—Uncorrected Proofs

350 DIAGNOSING AND TREATING ADULT CANCERS the associate medical director for surgery at the Nellie B. Connally Breast Center at MD Anderson. After completing medical school at the University of Maryland, she completed general surgery residency at the University of Southern California in Los Angeles, followed by a fellowship in surgical oncology at MDACC. During her surgical oncology fellowship, she also completed a research fellowship in the Department of Cancer Biology with Dr. Isaiah (Josh) Fidler. Her first faculty appointment was in the Depart- ment of Surgery at the University of California, San Diego, but she returned to MDACC in 2004 to join the faculty in surgical oncology. Dr. Hwang is a surgeon–scientist with a clinical focus on breast cancer as well as a research laboratory program focused on pancreatic cancer and triple-negative breast cancer. Her laboratory interest is in the tumor-associated stroma and its contributions to cancer progression, metastasis, and resistance to chemo- therapy and immunotherapy. She has served as a grant reviewer for numer- ous federal and private funding sources, including the National Institutes of Health/National Cancer Institute, U.S. Department of Defense, and the American Medical Association Foundation. Her clinical research interests are focused on optimizing surgical therapy for breast cancer, including the development of predictive tools for nodal involvement, minimally invasive approaches for breast cancer treatment, and the role of oncoplastic surgery for breast cancer patients. Nancy Keating, M.D., M.P.H., is a professor of health care policy and medicine at Harvard Medical School and a practicing general internist at Brigham and Women’s Hospital. Her research examines provider, patient, and health system factors that influence the delivery of high-quality care for individuals with cancer. She currently serves as the clinical lead on the Centers for Medicare & Medicaid Services Oncology Care Model Evalu- ation Team. She is an associate editor at the Journal of the National Can- cer Institute, a member of the editorial board of the Journal of Geriatric Oncology, and a member of the National Comprehensive Cancer Center Senior Oncology Guideline Panel. She completed 3-year terms on the Coun- cil of the Society of General Internal Medicine and the American Society of Clinical Oncology Clinical Practice Guidelines Committee. Dr. Keating was a member of the National Academies of Sciences, Engineering, and Medicine’s Committee on the Review of Clinical Guidance for the Care of Health Conditions Identified by the Camp Lejeune Legislation. She received her M.D. from the University of Chicago, Pritzker School of Medicine, and her M.P.H. from the Harvard School of Public Health. Anita J. Kumar, M.D., M.Sc., is an assistant professor of medicine at the Tufts University Medical Center and an assistant professor at the Tufts Clinical and Translational Science Institute and the Institute for Clinical PREPUBLICATION COPY—Uncorrected Proofs

APPENDIX A 351 Research and Health Policy Studies. Dr. Kumar is an attending and a health services researcher in hematologic malignancies, with a focus on improv- ing decision making and cancer care delivery for adults with lymphomas and leukemias from diagnosis through long-term survivorship. Her work includes identifying treatment patterns, health care use, and survival out- comes for patients with hematologic cancers who are treated in academic and community-based settings. Dr. Kumar was selected as the Komen Scholar in 2017 and is earning her doctoral degree in clinical and trans- lational science. She is a member of the American Society of Hematology and serves on the Committee on Communications and as a liaison to the Committee on Quality. Dr. Kumar was a co-organizer of the 2019 Boston- area chronic leukemia rounds for the Leukemia and Lymphoma Society. Dr. Kumar received her M.D. from the Albert Einstein College of Medicine and her M.Sc. in clinical epidemiology at the University of Pennsylvania.  Larissa Nekhlyudov, M.D., M.P.H., is a professor of medicine at the Har- vard Medical School, a practicing internist at the Brigham & Women’s Hospital in Boston, Massachusetts, and the clinical director of internal medicine for cancer survivors at the Dana-Farber Cancer Institute where she offers clinical consultations for long-term survivors of childhood and adult cancers. She is particularly interested in improving the care of cancer survivors and the interplay between primary and oncology care. Over the past decade, she has been at the forefront of the field of cancer survivor- ship, including the development of survivorship care policies and clinical guidelines, educational programs, and research. She is an active member of the Society of General Internal Medicine, the American Society of Clini- cal Oncology, and the National Comprehensive Cancer Network. She has previously served on several National Academies activities, including the Committee on the Quality of Cancer Care: Addressing the Challenges of an Aging Population and the Planning Committee for Long-Term Survivorship Care After Cancer Treatment: A Workshop. She received her M.D. from the Mount Sinai School of Medicine and completed residency training at Yale–New Haven Hospital/Yale Primary Care Residency Program. Kathryn Schmitz, Ph.D., M.P.H., FACSM, is a professor of public health sciences at The Pennsylvania State University College of Medicine. She is a clinical trialist who has led many exercise trials. Dr. Schmitz has also trans- lated her work into clinical practice. Dr. Schmitz has published more than 250 peer-reviewed scientific papers and has had $25 million in funding for her research since 2001. She was the lead author of the first American Col- lege of Sports Medicine (ACSM) Roundtable on Exercise for Cancer Sur- vivors, which published guidance for exercise testing and prescription for cancer survivors in July 2010. In June 2017 she became the president-elect PREPUBLICATION COPY—Uncorrected Proofs

352 DIAGNOSING AND TREATING ADULT CANCERS of ACSM. She assumed the presidency in June 2018 and as of June 2019 she became ACSM’s immediate past president. In March 2018 Dr. Schmitz chaired an International Multidisciplinary ACSM Roundtable on Exercise and Cancer Prevention and Control. The physicians, outpatient rehabilita- tion specialists, researchers, and exercise professionals in the room broadly agreed it is time for exercise oncology to go prime time. The question is how; Dr. Schmitz’ professional mission is to answer that question. Diane Von Ah, Ph.D., R.N., FAAN, is a professor at the Indiana University School of Nursing and a member of the Indiana University Melvin and Bren Simon Cancer Center. Her program of research focuses on advancing the state of the science in the area of cancer survivorship, including symptom management and quality of life. Her research combines clinical, behavioral, and basic sciences to address cancer symptom management, focusing pri- marily on cognitive impairment in breast cancer patients. Most recently, she has been funded to conduct a double-blind randomized controlled trial to examine the efficacy of cognitive training on cognitive performance in breast cancer survivors. Her work has been acknowledged by numerous awards, including induction as a fellow in the American Academy of Nurs- ing. She is an editorial board member of the National Institutes of Health, National Cancer Institute, Physician’s Data Query (PDQ) Supportive and Palliative Care Committee. She is an editorial board member for the Journal of Cancer Survivorship and Research in Nursing and Health. She received her Ph.D. from the University of Alabama at Birmingham and her postdoc- toral fellowship at Indiana University. CONSULTANT Howard H. Goldman, M.D., Ph.D., M.P.H., is a professor of psychiatry at the University of Maryland School of Medicine. His expertise is in evaluating mental health services and financing programs and policies. Dr. Goldman and his colleagues recently completed the Social Security Administration Mental Health Treatment Study, an experimental trial of supported employment and enhanced treatment for 2,200 Social Security Disability Insurance beneficiaries with schizophrenia or a mood disorder who are interested in working. He also served as the principal investiga- tor of the study team conducting the Evaluation of the Implementation and Impact of Mental Health and Substance Abuse Parity in the Federal Employees Health Benefits program, sponsored by the government. Dr. Goldman served as the senior scientific editor of the Surgeon General’s Report on Mental Health from 1997 to 1999, for which he was awarded the Surgeon General’s Medallion. During 2002 and 2003, Dr. Goldman was a consultant to the President’s New Freedom Commission on Mental PREPUBLICATION COPY—Uncorrected Proofs

APPENDIX A 353 Health. From 2004 to 2016 he served as the editor of Psychiatric Services, a mental health services research and policy journal published monthly by the American Psychiatric Association. He has served on the editorial boards of several other journals, including the American Journal of Psychiatry and the Journal of Mental Health Policy and Economics. He is a member of the National Academy of Social Insurance, having served on its disability policy panel. He is also a National Academy of Medicine member and currently serves as the chair of the National Academies of Siences, Engineering, and Medicine’s Standing Committee of Medical and Vocational Experts for the Social Security Administration’s Disability Programs and previously served on its Committee on Medical Evaluation of Veterans for Disability Com- pensation. Dr. Goldman received joint M.D.–M.P.H. degrees from Harvard University and a Ph.D. in social policy research from the Heller School at Brandeis University. PREPUBLICATION COPY—Uncorrected Proofs

PREPUBLICATION COPY—Uncorrected Proofs

Next: Appendix B: Public Workshop Agendas »
Diagnosing and Treating Adult Cancers and Associated Impairments Get This Book
×
Buy Paperback | $80.00
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Cancer is the second leading cause of death among adults in the United States after heart disease. However, improvements in cancer treatment and earlier detection are leading to growing numbers of cancer survivors. As the number of cancer survivors grows, there is increased interest in how cancer and its treatments may affect a person's ability to work, whether the person has maintained employment throughout the treatment or is returning to work at a previous, current, or new place of employment. Cancer-related impairments and resulting functional limitations may or may not lead to disability as defined by the U.S. Social Security Administration (SSA), however, adults surviving cancer who are unable to work because of cancer-related impairments and functional limitations may apply for disability benefits from SSA.

At the request of SSA, Diagnosing and Treating Adult Cancers and Associated Impairments provides background information on breast cancer, lung cancer, and selected other cancers to assist SSA in its review of the listing of impairments for disability assessments. This report addresses several specific topics, including determining the latest standards of care as well as new technologies for understanding disease processes, treatment modalities, and the effect of cancer on a person's health and functioning, in order to inform SSA's evaluation of disability claims for adults with cancer.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  6. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  7. ×

    View our suggested citation for this chapter.

    « Back Next »
  8. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!